Amneal Pharmaceuticals Stock Price, News & Analysis (NYSE:AMRX)

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued twelve-month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they predict the company's share price to reach $4.80 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $1.99 on January 1st, 2023. Since then, AMRX stock has increased by 134.2% and is now trading at $4.66.
View the best growth stocks for 2023 here.

Amneal Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,620,000 shares, an increase of 13.5% from the October 31st total of 3,190,000 shares. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 6.5% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our AMRX earnings forecast.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its quarterly earnings data on Tuesday, November, 7th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.07. The company had revenue of $620.04 million for the quarter, compared to analysts' expectations of $613.74 million. Amneal Pharmaceuticals had a net margin of 0.43% and a trailing twelve-month return on equity of 109.82%.

Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Monday, October, 23rd. The company provided earnings per share guidance of $0.51-0.58 for the period, compared to the consensus EPS estimate of $0.55. The company issued revenue guidance of $2.37-2.42 billion, compared to the consensus revenue estimate of $2.38 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (1.31%), Rubric Capital Management LP (1.31%), LSV Asset Management (0.47%), Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.39%) and AQR Capital Management LLC (0.31%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.